Iterum Therapeutics plc [NASDAQ: ITRM] plunged by -$0.01 during the normal trading session on Wednesday and reaching a high of $0.6794 during the day while it closed the day at $0.65. The company report on November 30, 2020 that Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem.
–First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved–.
–Potential Approval Q3 2021 with Priority Review–.
Iterum Therapeutics plc stock has also loss -20.73% of its value over the past 7 days. However, ITRM stock has declined by -4.26% in the 3 months of the year. Over the past six months meanwhile, it has lost -56.38% and lost -85.56% year-on date.
The market cap for ITRM stock reached $29.22 million, with 43.04 million shares outstanding and 42.11 million shares in the current float. Compared to the average trading volume of 6.57M shares, ITRM reached a trading volume of 3707713 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Iterum Therapeutics plc [ITRM]:
RBC Capital Mkts have made an estimate for Iterum Therapeutics plc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on June 02, 2020. The new note on the price target was released on January 21, 2020, representing the official price target for Iterum Therapeutics plc stock.
The Average True Range (ATR) for Iterum Therapeutics plc is set at 0.06
ITRM stock trade performance evaluation
Iterum Therapeutics plc [ITRM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.73. With this latest performance, ITRM shares gained by 41.27% in over the last four-week period, additionally sinking by -56.38% over the last 6 months – not to mention a drop of -79.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ITRM stock in for the last two-week period is set at 49.87, with the RSI for the last a single of trading hit 51.49, and the three-weeks RSI is set at 49.18 for Iterum Therapeutics plc [ITRM]. The present Moving Average for the last 50 days of trading for this stock 0.7142, while it was recorded at 0.7202 for the last single week of trading, and 1.6173 for the last 200 days.
Iterum Therapeutics plc [ITRM]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Iterum Therapeutics plc [ITRM] shares currently have an operating margin of -275732.43. Iterum Therapeutics plc’s Net Margin is presently recorded at -278729.73.
Return on Total Capital for ITRM is now -254.31, given the latest momentum, and Return on Invested Capital for the company is -283.18. Return on Equity for this stock declined to -454.48, with Return on Assets sitting at -166.85.
Reflecting on the efficiency of the workforce at the company, Iterum Therapeutics plc [ITRM] managed to generate an average of -$2,343,864 per employee. Receivables Turnover for the company is 0.04 with a Total Asset Turnover recorded at a value of 0.00.Iterum Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
Earnings per share (EPS) analysis for Iterum Therapeutics plc [ITRM] stock
With the latest financial reports released by the company, Iterum Therapeutics plc posted -1.59/share EPS, while the average EPS was predicted by analysts to be reported at -1.7/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ITRM.
Iterum Therapeutics plc [ITRM]: Insider Ownership positions
There are presently around $3 million, or 17.10% of ITRM stock, in the hands of institutional investors. The top three institutional holders of ITRM stocks are: CANAAN PARTNERS X LLC with ownership of 1,733,170, which is approximately 0% of the company’s market cap and around 0.60% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 1,538,316 shares of the stock with an approximate value of $1.0 million in ITRM stocks shares; and NEW LEAF VENTURE PARTNERS, L.L.C., currently with $0.95 million in ITRM stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Iterum Therapeutics plc stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 6 institutional holders increased their position in Iterum Therapeutics plc [NASDAQ:ITRM] by around 94,170 shares. Additionally, 5 investors decreased positions by around 1,299,326 shares, while 5 investors held positions by with 3,581,387 shares. The mentioned changes placed institutional holdings at 4,974,883 shares, according to the latest SEC report filing. ITRM stock had 5 new institutional investments in for a total of 84,215 shares, while 4 institutional investors sold positions of 1,297,040 shares during the same period.